SCHEMBL5357841

SCHEMBL5357841

O=C(O)c1cc(Cl)cnc1Oc1ccc2c(c1)OCO2

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 3/20 0.49
KMT2A Q03164 3/20 0.49
NPC1 O15118 2/20 0.49
MAOB P27338 1/20 0.45
LMNA P02545 4/20 0.44
SMN1; SMN2 Q16637 3/20 0.44
TP53 P04637 1/20 0.44
PTGER4 P35408 5/20 0.43
MAPK1 P28482 3/20 0.43
PTGER2 P43116 2/20 0.43
HPGD P15428 1/20 0.43
ALOX15 P16050 1/20 0.43
POLB P06746 1/20 0.43
TSHR P16473 3/20 0.42
MAPT P10636 1/20 0.42
NPSR1 Q6W5P4 1/20 0.42
ALDH1A1 P00352 2/20 0.42
PDE4A P27815 1/20 0.42
PDE4B Q07343 1/20 0.42
PDE4C Q08493 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5359310 0.85 PTGER4 (0.46) RAB9AKMT2ANPC1MAOBLMNA
SCHEMBL6611896 0.81 LMNA (0.45) RAB9AKMT2ANPC1MAOBLMNA
SCHEMBL5359868 0.80 LMNA (0.60) RAB9AKMT2ANPC1MAOBLMNA
SCHEMBL1271610 0.78 PTGER4 (0.52) LMNASMN1; SMN2PTGER4MAPK1PTGER2
SCHEMBL4443148 0.77 PTGER4 (0.65) LMNASMN1; SMN2PTGER4MAPK1PTGER2
SCHEMBL5354892 0.76 PTGER4 (0.53) KMT2ALMNAPTGER4MAPK1PTGER2
SCHEMBL1656724 0.76 ALDH1A1 (0.57) RAB9AKMT2ANPC1MAOBLMNA
SCHEMBL5360226 0.74 PTGER4 (0.51) KMT2ALMNAPTGER4MAPK1PTGER2
SCHEMBL8280178 0.73 PTGER4 (0.53) KMT2APTGER4MAPK1PTGER2ALDH1A1
SCHEMBL5363828 0.73 PTGER4 (0.64) PTGER4PTGER2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7250518-B2 Nicotinamide acids, amides, and their mimetics active as inhibitors of PDE4 isozymes PFIZER INC. (US) 2007-07-31 US disclosed
US-7250518-B2 Nicotinamide acids, amides, and their mimetics active as inhibitors of PDE4 isozymes PFIZER INC. (US) 2007-07-31 US disclosed
US-7250518-B2 Nicotinamide acids, amides, and their mimetics active as inhibitors of PDE4 isozymes PFIZER INC. (US) 2007-07-31 US disclosed
EP-1229034-B1 Nicotinamide derivatives and their mimetics as inhibitors of PDE4 isozymes PFIZER PROD INC (US) 2005-04-13 EP disclosed
EP-1229034-B1 Nicotinamide derivatives and their mimetics as inhibitors of PDE4 isozymes PFIZER PROD INC (US) 2005-04-13 EP disclosed
US-20040171798-A1 Nicotinamide acids, amides, and their mimetics active as inhibitors of PDE4 isozymes PFIZER INC 2004-09-02 US disclosed
US-20020111495-A1 Nicotinamide acids, amides, and their mimetics active as inhibitors of PDE4 isozymes PFIZER INC. 2002-08-15 US disclosed
EP-1229034-A1 Nicotinamide derivatives and their mimetics as inhibitors of PDE4 isozymes Pfizer Products Inc. (US) 2002-08-07 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040171798-A1 Nicotinamide acids, amides, and their mimetics active as inhibitors of PDE4 isozymes NOX3, PDE4A, NOX1 RAB9A 1564/4885KMT2A 3049/4885NPC1 2685/4885
US-20020111495-A1 Nicotinamide acids, amides, and their mimetics active as inhibitors of PDE4 isozymes NOX3, NOX1, NOX4 RAB9A 2400/4885KMT2A 3442/4885NPC1 2800/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.